Beyond Air, Inc. (XAIR) Reports $2.3M Quarterly Revenue, Reaffirms Guidance

Beyond Air reported $2.3M in Q2 revenue, up from $1.8M a year ago, with a net loss of $7.8M. The company reaffirmed its revenue guidance of $8M for 2026 and $16M–$18M for 2027, pending FDA approval for its second-generation system.

Original reporting
Published Nov 11, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Beyond Air, Inc. (XAIR) Reports $2.3M Quarterly Revenue, Reaffirms Guidance — source image
Decision brief

The 30-second read

$XAIRNeutralMed
01

Why it matters

The earnings release provides fresh guidance that could attract growth‑oriented investors, but the sizable loss and regulatory risk may limit upside.

02

Market read

Micro‑cap earnings with modest revenue growth and significant regulatory risk; relevant for niche biotech traders.

03

What to watch

Potential partnership or licensing deals not mentioned could materially affect future revenue.

Relevance 6/10Novelty 6/10Timing: post‑market release

Background

Beyond Air is an early‑stage medical‑device company reporting its first quarterly revenue growth while still awaiting regulatory clearance for its next‑generation system.

Company-level read

Ticker impact

$XAIRNeutralMedium confidence
Context

Beyond Air disclosed Q3 revenue of $2.3M, net loss of $7.8M and reaffirmed FY2026 guidance of $8M, plus FY2027 guidance of $16M‑$18M pending FDA approval.

Expected impact

modest upside if revenue trajectory holds; downside risk from continued losses and regulatory uncertainty

Evidence & confidence

Guidance increase signals growth, but the loss and pending FDA decision keep investors cautious.

Market effects

Highlights ongoing risk in the medical‑device sector tied to FDA approvals.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal global impact; only relevant to niche biotech/medical‑device participants.

Counterpoint

The reaffirmed guidance may be overly optimistic given the pending FDA review; price could fall on any delay.

Key entities

  • Beyond Air, Inc.

    Medical‑device developer reporting Q3 results.

Related articles

$XAIRLow

Beyond Air Reports Financial Results and Provides Corporate Update

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026 Record quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH PM

$XAIRMed

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last ye

$XAIRMed

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement fo

$XAIRMed

Beyond Air, Inc. Q1 2027 Earnings Call Summary

Beyond Air, Inc. reported Q1 2027 revenue of $1.8 million, citing long hospital contracting cycles. Management said its sales pipeline doubled and secured a national GPO agreement. It reaffirmed 2026 revenue guidance of $8 million and projected 2027 revenue of $16-$18 million, tied to Gen II LungFit PH FDA timing. A $30 million financing supports Gen II launch.

$XAIRMed

Beyond Air (XAIR) Q1 2027 Earnings Call Transcript

Beyond Air (XAIR) held a Q1 2027 earnings call. It reported Q ended June 30, 2026 revenue of $1.8 million, flat vs the prior quarter, with gross margin rising to 13% from 9%. The company reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million, pending FDA approval for its Gen II LungFit PH system. It also entered a national GPO deal and announced financing up to $30 million.